News
Madiha Derouazi and Elodie Belnoue named as joint finalists for European Inventor Award 2022
Geneva, 17 May 2022 – We are very happy and proud to announce that Madiha Derouazi and Elodie Belnoue have been jointly nominated for the EPO's European Inventor Award 2022.
Joint Team Effort Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer
AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies in patients with colorectal cancer in combination with Ezabenlimab (BI 754091).
Season Greetings - 2022
A very happy holiday season from the whole AMAL team, and a great start into 2022 !
AMAL Therapeutics to publish research outcomes in Cancers
Geneva, Switzerland, December 3, 2021 – AMAL Therapeutics announced today that the latest findings of its research team is on line on the Cancers website.
AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website
Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research team, in collaboration with Prof. Guido Wollman’s lab at the Medical University of Innsbruck, is online on the Nature Communication website. The results show that combinatorial treatment with a protein-based cancer vaccine and an oncolytic virus elicits a potent immune response resulting in long lasting anti-tumoral efficacy in different tumor models, highlighting the potential for cancer treatment.